Moderna Says Early Coronavirus Vaccine Shows Promise
2020-05-19
LRC
TXT
大字
小字
滚动
全页
1American drug maker Moderna said Monday that its experimental COVID-19 vaccine produced antibodies in a small group of healthy people in an early trial.
2The company said eight people who received two small amounts of its vaccine developed antibodies similar to those developed by people who have recovered from the disease.
3The U.S. National Institute of Allergy and Infectious Diseases led the experiment, also called a trial.
4It involved 45 volunteers who received one or two shots of differing amounts of the vaccine.
5Tal Zaks is the chief medical officer at Moderna.
6Based on early results of the trial, he said the vaccine "has the potential to prevent COVID-19 disease...."
7He also said the company now can better choose the vaccine amount needed for further experiments.
8The testing involved three different amounts.
9Zaks said the two smaller amounts of vaccine seem safe and the larger amount caused some short-term side effects.
10Three study subjects developed "flu-like" conditions following a second shot of the large dose.
11Moderna said it plans to drop that amount for the next part of the trial.
12Amesh Adalja is an infectious disease expert at the Johns Hopkins Center for Health Security who was not involved in the study.
13He told Reuters that the findings are meaningful, but noted that they come from only eight people.
14"It was designed for safety. Not for efficacy," he said.
15Moderna has been permitted to start a second part of human testing that will involve several hundreds of people.
16In April, the U.S. government gave the company $483 million for vaccine development.
17Last week, U.S. officials gave the vaccine special recognition to help speed the process for approval.
18Stéphane Bancel, Chief Executive Officer of Moderna, said the company is hoping to start part three of the study in July.
19The company will try to find the lowest amount of vaccine necessary to protect people.
20In May, Moderna and the biotechnology company Lonza agreed to work together over the next ten years to make a vaccine.
21The partnership could lead to the manufacture of 1 billion COVID-19 vaccine treatments a year.
22There are currently no approved treatments or vaccines for COVID-19.
23Almost 4.8 million people are confirmed to have had the virus.
24It is known to have killed about 320,000.
25However, experts think the numbers may be underreported.
26The World Health Organization has listed more than 100 efforts to develop effective treatments and vaccines for the coronavirus.
27The list includes clinical trials in China, at the University of Oxford, and with American drug makers Pfizer, Inovio and Moderna.
28Experts predict a safe and effective vaccine could take 12 to 18 months to develop.
29The results of Moderna's early trial have not been published.
30But the news lifted the company's stock prices and spread hope that a solution against the infectious disease might be close.
31I'm Jonathan Evans.
1American drug maker Moderna said Monday that its experimental COVID-19 vaccine produced antibodies in a small group of healthy people in an early trial. 2The company said eight people who received two small amounts of its vaccine developed antibodies similar to those developed by people who have recovered from the disease. 3The U.S. National Institute of Allergy and Infectious Diseases led the experiment, also called a trial. It involved 45 volunteers who received one or two shots of differing amounts of the vaccine. 4Tal Zaks is the chief medical officer at Moderna. Based on early results of the trial, he said the vaccine "has the potential to prevent COVID-19 disease...." He also said the company now can better choose the vaccine amount needed for further experiments. 5The testing involved three different amounts. Zaks said the two smaller amounts of vaccine seem safe and the larger amount caused some short-term side effects. Three study subjects developed "flu-like" conditions following a second shot of the large dose. Moderna said it plans to drop that amount for the next part of the trial. 6Amesh Adalja is an infectious disease expert at the Johns Hopkins Center for Health Security who was not involved in the study. He told Reuters that the findings are meaningful, but noted that they come from only eight people. "It was designed for safety. Not for efficacy," he said. 7Moderna has been permitted to start a second part of human testing that will involve several hundreds of people. In April, the U.S. government gave the company $483 million for vaccine development. Last week, U.S. officials gave the vaccine special recognition to help speed the process for approval. 8Stéphane Bancel, Chief Executive Officer of Moderna, said the company is hoping to start part three of the study in July. The company will try to find the lowest amount of vaccine necessary to protect people. 9In May, Moderna and the biotechnology company Lonza agreed to work together over the next ten years to make a vaccine. The partnership could lead to the manufacture of 1 billion COVID-19 vaccine treatments a year. 10There are currently no approved treatments or vaccines for COVID-19. Almost 4.8 million people are confirmed to have had the virus. It is known to have killed about 320,000. However, experts think the numbers may be underreported. 11The World Health Organization has listed more than 100 efforts to develop effective treatments and vaccines for the coronavirus. The list includes clinical trials in China, at the University of Oxford, and with American drug makers Pfizer, Inovio and Moderna. 12Experts predict a safe and effective vaccine could take 12 to 18 months to develop. The results of Moderna's early trial have not been published. But the news lifted the company's stock prices and spread hope that a solution against the infectious disease might be close. 13I'm Jonathan Evans. 14Hai Do adapted this story for Learning English based on Associated Press and Reuters news reports. Caty Weaver was the editor. 15_________________________________________________________ 16Words in This Story 17potential - n. a chance or possibility that something will happen in the future 18efficacy - n. the power to produce a desired result or effect 19clinical - adj. relating or based on work done with real patients